Underuse of antiplatelets and inappropriate use

Mark Naunton, Michiel Duyvendak

Research output: Contribution to journalLetter

Abstract

We have read the findings by Monesi et al. in the Journal on the appropriateness of antiplatelet therapies in a large cross-sectional study in Italy [1]. Not surprisingly, they found low use of antiplatelets for primary and secondary prevention. We have a few comments and questions regarding their paper. The authors do not mention specifically how the drug treatments were collected. Were patients questioned by their doctors at the time of study, or were the data obtained from pharmacies? We are also curious as to why patients with atrial fibrillation were excluded from this study. Although we agree that most patients should be considered for antithrombotic therapy (i.e., warfarin), there are sufficient data to support the use of aspirin in individuals with atrial fibrillation who are at fairly low absolute risk of stroke or who have contraindications to warfarin [2]. Furthermore, the authors did not show which other medications the patients were receiving that may have made low-dose aspirin inappropriate (for instance, warfarin for deep vein thrombosis prophylaxis, current nonsteroidal antiinflammatory or prednisolone use, and so on).
Original languageEnglish
Pages (from-to)81-82
Number of pages2
JournalEuropean Journal of Clinical Pharmacology
Volume62
Issue number1
DOIs
Publication statusPublished - 1 Jan 2006
Externally publishedYes

Fingerprint

Warfarin
Atrial Fibrillation
Aspirin
Time and Motion Studies
Pharmacies
Primary Prevention
Secondary Prevention
Prednisolone
Venous Thrombosis
Italy
Anti-Inflammatory Agents
Therapeutics
Cross-Sectional Studies
Stroke
Pharmaceutical Preparations

Cite this

@article{10ee34a5f11a4db499706f167eb5e34c,
title = "Underuse of antiplatelets and inappropriate use",
abstract = "We have read the findings by Monesi et al. in the Journal on the appropriateness of antiplatelet therapies in a large cross-sectional study in Italy [1]. Not surprisingly, they found low use of antiplatelets for primary and secondary prevention. We have a few comments and questions regarding their paper. The authors do not mention specifically how the drug treatments were collected. Were patients questioned by their doctors at the time of study, or were the data obtained from pharmacies? We are also curious as to why patients with atrial fibrillation were excluded from this study. Although we agree that most patients should be considered for antithrombotic therapy (i.e., warfarin), there are sufficient data to support the use of aspirin in individuals with atrial fibrillation who are at fairly low absolute risk of stroke or who have contraindications to warfarin [2]. Furthermore, the authors did not show which other medications the patients were receiving that may have made low-dose aspirin inappropriate (for instance, warfarin for deep vein thrombosis prophylaxis, current nonsteroidal antiinflammatory or prednisolone use, and so on).",
author = "Mark Naunton and Michiel Duyvendak",
year = "2006",
month = "1",
day = "1",
doi = "10.1007/s00228-005-0049-z",
language = "English",
volume = "62",
pages = "81--82",
journal = "European Journal of Clinical Pharmacology",
issn = "0031-6970",
publisher = "Springer Verlag",
number = "1",

}

Underuse of antiplatelets and inappropriate use. / Naunton, Mark; Duyvendak, Michiel.

In: European Journal of Clinical Pharmacology, Vol. 62, No. 1, 01.01.2006, p. 81-82.

Research output: Contribution to journalLetter

TY - JOUR

T1 - Underuse of antiplatelets and inappropriate use

AU - Naunton, Mark

AU - Duyvendak, Michiel

PY - 2006/1/1

Y1 - 2006/1/1

N2 - We have read the findings by Monesi et al. in the Journal on the appropriateness of antiplatelet therapies in a large cross-sectional study in Italy [1]. Not surprisingly, they found low use of antiplatelets for primary and secondary prevention. We have a few comments and questions regarding their paper. The authors do not mention specifically how the drug treatments were collected. Were patients questioned by their doctors at the time of study, or were the data obtained from pharmacies? We are also curious as to why patients with atrial fibrillation were excluded from this study. Although we agree that most patients should be considered for antithrombotic therapy (i.e., warfarin), there are sufficient data to support the use of aspirin in individuals with atrial fibrillation who are at fairly low absolute risk of stroke or who have contraindications to warfarin [2]. Furthermore, the authors did not show which other medications the patients were receiving that may have made low-dose aspirin inappropriate (for instance, warfarin for deep vein thrombosis prophylaxis, current nonsteroidal antiinflammatory or prednisolone use, and so on).

AB - We have read the findings by Monesi et al. in the Journal on the appropriateness of antiplatelet therapies in a large cross-sectional study in Italy [1]. Not surprisingly, they found low use of antiplatelets for primary and secondary prevention. We have a few comments and questions regarding their paper. The authors do not mention specifically how the drug treatments were collected. Were patients questioned by their doctors at the time of study, or were the data obtained from pharmacies? We are also curious as to why patients with atrial fibrillation were excluded from this study. Although we agree that most patients should be considered for antithrombotic therapy (i.e., warfarin), there are sufficient data to support the use of aspirin in individuals with atrial fibrillation who are at fairly low absolute risk of stroke or who have contraindications to warfarin [2]. Furthermore, the authors did not show which other medications the patients were receiving that may have made low-dose aspirin inappropriate (for instance, warfarin for deep vein thrombosis prophylaxis, current nonsteroidal antiinflammatory or prednisolone use, and so on).

UR - http://www.scopus.com/inward/record.url?scp=30844432877&partnerID=8YFLogxK

U2 - 10.1007/s00228-005-0049-z

DO - 10.1007/s00228-005-0049-z

M3 - Letter

VL - 62

SP - 81

EP - 82

JO - European Journal of Clinical Pharmacology

JF - European Journal of Clinical Pharmacology

SN - 0031-6970

IS - 1

ER -